Phellodendron amurense Rupr. Polysaccharides protects against diabetic nephropathy via alteration of PI3K/GSK-3β/Nrf2/TGF-β/Smad signaling pathway and gut microbiota

doi:10.1007/s13659-025-00566-z

Abstract

Abstract: In this study, a diabetic nephropathy (DN) rat model was established using 2% Streptozocin (STZ) solution, and an in vitro DN model was constructed by stimulating HK-2 cells with 30 mM glucose to investigate the mechanism of Phellodendron amurense Rupr. Polysaccharides (PAP) in ameliorating DN. Results demonstrated that PAP, a neutral homogeneous polysaccharide with molecular weight of 1.98 × 105 Da composed of Rha, GalA, Gal, and D-Xyl, exerted renal protective effects through multiple pathways. It enhanced renal antioxidant capacity and alleviated oxidative damage in DN by upregulating PI3K/AKT pathway-related protein expression. Simultaneously, PAP activated the TGF-β/Smad pathway via Nrf2 to mitigate renal fibrosis symptoms in DN, while inhibiting cellular apoptosis. Furthermore, PAP suppressed renal inflammation through gut microbiota reduction, thereby protecting against renal injury in DN rats. This study reveals that PAP alleviates DN symptoms by modulating gut microbiota, enhancing antioxidant and anti-fibrotic capacities, and inhibiting apoptotic pathways, comprehensively elucidating its multifaceted therapeutic mechanisms against DN.

Key words: Phellodendron amurense Rupr. Polysaccharides, Diabetic nephropathy, Gut microbiota

摘要： In this study, a diabetic nephropathy (DN) rat model was established using 2% Streptozocin (STZ) solution, and an in vitro DN model was constructed by stimulating HK-2 cells with 30 mM glucose to investigate the mechanism of Phellodendron amurense Rupr. Polysaccharides (PAP) in ameliorating DN. Results demonstrated that PAP, a neutral homogeneous polysaccharide with molecular weight of 1.98 × 105 Da composed of Rha, GalA, Gal, and D-Xyl, exerted renal protective effects through multiple pathways. It enhanced renal antioxidant capacity and alleviated oxidative damage in DN by upregulating PI3K/AKT pathway-related protein expression. Simultaneously, PAP activated the TGF-β/Smad pathway via Nrf2 to mitigate renal fibrosis symptoms in DN, while inhibiting cellular apoptosis. Furthermore, PAP suppressed renal inflammation through gut microbiota reduction, thereby protecting against renal injury in DN rats. This study reveals that PAP alleviates DN symptoms by modulating gut microbiota, enhancing antioxidant and anti-fibrotic capacities, and inhibiting apoptotic pathways, comprehensively elucidating its multifaceted therapeutic mechanisms against DN.

关键词: Phellodendron amurense Rupr. Polysaccharides, Diabetic nephropathy, Gut microbiota

Mei Mei, Huawei Sun, Kai Zhang, Feng Zhang, Shiqing Sun, Yu Zhang. Phellodendron amurense Rupr. Polysaccharides protects against diabetic nephropathy via alteration of PI3K/GSK-3β/Nrf2/TGF-β/Smad signaling pathway and gut microbiota[J]. Natural Products and Bioprospecting, 2026, 16(1): 13-13.

References

[1] Anil Kumar P, Welsh GI, Saleem MA, Menon RK. Molecular and cellular events mediating glomerular podocyte dysfunction and depletion in diabetes mellitus. Front Endocrinol (Lausanne). 2014;25(5):151. https://doi.org/10.3389/fendo.2014.00151.
[2] Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–25. https://doi.org/10.2337/diabetes.54.6.1615.
[3] Chebotareva N, Vinogradov A, McDonnell V, Zakharova NV, Indeykina MI, Moiseev S, et al. Urinary protein and peptide markers in chronic kidney disease. Int J Mol Sci. 2021;22(22):1–20. https://doi.org/10.3390/ijms222212123.
[4] Chen D-Q, Zhang H-J, Zhang W, Feng K, Liu H, Zhao H-L, et al. Tangshen formula alleviates inflammatory injury against aged diabetic kidney disease through modulating gut microbiota composition and related amino acid metabolism. Exp Gerontol. 2024;188(1):1–13. https://doi.org/10.1016/j.exger.2024.112393.
[5] Chen J, Ding X, Wu R, Tong B, Zhao L, Lv H, et al. Novel sesquiterpene glycoside from loquat leaf alleviates type 2 diabetes mellitus combined with nonalcoholic fatty liver disease by improving insulin resistance, oxidative stress, inflammation, and gut microbiota composition. J Agric Food Chem. 2021;69(47):14176–91. https://doi.org/10.1021/acs.jafc.1c05596.
[6] Dong W, Zhao Y, Li X, Huo J, Wang W. Corn silk polysaccharides attenuate diabetic nephropathy through resto ration of the gut microbial ecosystem and metabolic homeostasis. Front Endocrinol. 2023;14:123–32. https://doi.org/10.3389/fendo.2023.1232132.
[7] Feng SY, Wu SJ, Chang YC, Ng LT, Chang SJ. Stimulation of GLUT4 glucose uptake by anthocyanin-rich extract from black rice (Oryza sativa L.) via PI3K/Akt and AMPK/p38 MAPK signaling in C2C12 cells. Metabolites. 2022;12(9):856–66. https://doi.org/10.3390/metabo12090856.
[8] Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504(7480):446–50. https://doi.org/10.1038/nature12721.
[9] Galoian K, Temple HT, Galoyan A. mTORC1 inhibition and ECM-cell adhesion-independent drug resistance via PI3K-AKT and PI3K-RAS-MAPK feedback loops. Tumour Biol. 2012;33(3):885–90. https://doi.org/10.1007/s13277-011-0315-x.
[10] Gao J, Ma L, Yin J, Li TJ, Yin YL, Chen YZ. Canola oil ameliorates obesity by suppressing lipogenesis and reprogramming the gut microbiota in mice via the AMPK pathway. Nutrients. 2024;16(19):17–27. https://doi.org/10.3390/nu16193379.
[11] Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164–76. https://doi.org/10.2337/diacare.28.1.164.
[12] Guo H, Fu M-X, Wu D-T, Zhao Y-X, Li H, Li H-B, et al. Structural characteristics of crude polysaccharides from 12 selected c hinese teas, and their antioxidant and anti-diabetic activities. Antioxidants. 2021;10(10):1562–77. https://doi.org/10.3390/antiox10101562.
[13] Guo Y, Guo C, Ha W, Ding Z. Carnosine improves diabetic retinopathy via the MAPK/ERK pathway. Exp Ther Med. 2019;17(4):2641–7. https://doi.org/10.3892/etm.2019.7223.
[14] Hsu YH, Chen TH, Wu MY, Lin YF, Chen WL, Cheng TH, et al. Protective effects of Zhibai Dihuang Wan on renal tubular cells affected with gentamicin-induced apoptosis. J Ethnopharmacol. 2014;151(1):635–42. https://doi.org/10.1016/j.jep.2013.11.031.
[15] Jiang H, Zhang Y, Xu D, Wang Q. Probiotics ameliorates glycemic control of patients with diabetic neph ropathy: a randomized clinical study. J Clin Lab Anal. 2021;35(4):1–8. https://doi.org/10.1002/jcla.23650.
[16] Jing D, Bai H, Yin S. Renoprotective effects of emodin against diabetic nephropathy in rat models are mediated via PI3K/Akt/GSK-3β and Bax/caspase-3 signaling pathways. Exp Ther Med. 2017;14(5):5163–9. https://doi.org/10.3892/etm.2017.5131.
[17] Lee Y, Kim H, Choi HS, Kang BH, Han YB, Kim SJ. Effects of water extract of 1:1 mixture of Phellodendron cortex and Aralia cortex on polyol pathway and oxidative damage in lenses of diabetic rats. Phytother Res. 1999;13(7):555–60.
[18] Li J, Wu B, Hu H, Fang X, Liu Z, Wu S. GdCl(3) attenuates the glomerular sclerosis of streptozotocin (STZ) induced diabetic rats via inhibiting TGF-β/Smads signal pathway. J Pharmacol Sci. 2020;142(2):41–9. https://doi.org/10.1016/j.jphs.2019.06.008.
[19] Li X, Zhang Y, Xing X, Li M, Liu Y, Xu A, et al. Podocyte injury of diabetic nephropathy: novel mechanism discovery and therapeutic prospects. Biomed pharmacother. 2023;168(115670):1–16. https://doi.org/10.1016/j.biopha.2023.115670.
[20] Lin E, Kuo PH, Liu YL, Yang AC, Tsai SJ. Transforming growth factor-β signaling pathway-associated genes SMAD2 and TGFBR2 are implicated in metabolic syndrome in a Taiwanese population. Sci Rep. 2017;7(1):1–18. https://doi.org/10.1038/s41598-017-14025-4.
[21] Liu L, Huang W, Wang J, Song H, Cen J, Ji B. Anthraquinone derivative exerted hormetic effect on the apoptosis in oxygen-glucose deprivation-induced PC12 cells via ERK and Akt activated Nrf2/HO-1 signaling pathway. Chem Biol Interact. 2017;262(1):1–11. https://doi.org/10.1016/j.cbi.2016.12.001.
[22] Liu X, Yang H, Liu Z. Signaling pathways involved in paraquat-induced pulmonary toxicity: molecular mechanisms and potential therapeutic drugs. Int Immunopharmacol. 2022;113(109301):1–14. https://doi.org/10.1016/j.intimp.2022.109301.
[23] Nova E, de Pérez Heredia F, Gómez-Martínez S, Marcos A. The role of probiotics on the microbiota. Nutr Clin Pract. 2016;31(3):387–400. https://doi.org/10.1177/0884533615620350.
[24] Pan S, Jiang S-s, Li R, Tian B, Huang C-y, Wang R, et al. Hong Guo Ginseng Guo (HGGG) protects against kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome and regulating intestinal flora. Phytomedicine. 2024;132(1):1–12. https://doi.org/10.1016/j.phymed.2024.155861.
[25] Ramasubbu K, Devi Rajeswari V. Impairment of insulin signaling pathway PI3K/Akt/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review. Mol Cell Biochem. 2023;478(6):1307–24. https://doi.org/10.1007/s11010-022-04587-x.
[26] Ren LL, Li XJ, Duan TT, Li ZH, Yang JZ, Zhang YM, et al. Transforming growth factor-β signaling: from tissue fibrosis to therapeutic opportunities. Chem Biol Interact. 2023;369:110289. https://doi.org/10.1016/j.cbi.2022.110289.
[27] Selby NM, Taal MW. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020;22(1):3–15. https://doi.org/10.1111/dom.14007.
[28] Sharpton SR, Ajmera V, Loomba R. Emerging role of the gut microbiome in nonalcoholic fatty liver disease: from composition to function. Clin Gastroenterol Hepatol. 2019;17(2):296–306. https://doi.org/10.1016/j.cgh.2018.08.065.
[29] Tan H, Chen J, Li Y, Li Y, Zhong Y, Li G, et al. Glabridin, a bioactive component of licorice, ameliorates diabetic nephropathy by regulating ferroptosis and the VEGF/Akt/ERK pathways. Mol Med. 2022;28(1):58–78. https://doi.org/10.1186/s10020-022-00481-w.
[30] Tang G, Li S, Zhang C, Chen H, Wang N, Feng Y. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management. Acta Pharm Sin B. 2021;11(9):2749–67. https://doi.org/10.1016/j.apsb.2020.12.020.
[31] Wada T, Shimizu M, Toyama T, Hara A, Kaneko S, Furuichi K. Clinical impact of albuminuria in diabetic nephropathy. Clin Exp Nephrol. 2012;16(1):96–101. https://doi.org/10.1007/s10157-011-0508-z.
[32] Wan J, Long Y, Zhang Y, Liu S, Shi A, Yu S, et al. Role of PI3K/Akt signaling pathway in diabetic nephropathy and research progress on intervention of traditional Chinese medicine. Chin Tradit Herbal Drugs. 2021;52(12):3705–16.
[33] Wang N, Xu P, Yao W, Zhang J, Liu S, Wang Y, et al. Structural elucidation and anti-diabetic osteoporotic activity of an arabinogalactan from Phellodendron chinense Schneid. Carbohydr Polym. 2021;271(1):1–10. https://doi.org/10.1016/j.carbpol.2021.118438.
[34] Wang Y, He W. Improving the dysregulation of FoxO1 activity is a potential therapy for alleviating diabetic kidney disease. Front Pharmacol. 2021;12:630617. https://doi.org/10.3389/fphar.2021.630617.
[35] Wang YY, Jiang H, Pan J, Huang XR, Wang YC, Huang HF, et al. Macrophage-to-myofibroblast transition contributes to interstitial fibrosis in chronic renal allograft injury. J Am Soc Nephrol. 2017;28(7):2053–67. https://doi.org/10.1681/ASN.2016050573.
[36] Warner DR, Warner JB, Abdelfadil Y, Hardesty JE, Treves R, Lei C, et al. Effects of soluble epoxide hydrolase inhibition on liver injury and gut microbiota in mice chronically fed ethanol. Alcohol Clin Exp Res. 2025;49(8):1730–43. https://doi.org/10.1111/acer.70109.
[37] Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol. 2014;39(3):230–7. https://doi.org/10.1159/000360010.
[38] Xu J, Wang F, Hu CQ, Lai JX, Xie SW, Yu KF, et al. Dietary high plant protein and high lipid impaired the intestine health of grouper by disrupting oxidative stress, immune response, and protein metabolism. Aquac Rep. 2024;39(1):1–15. https://doi.org/10.1016/j.aqrep.2024.102389.
[39] Xu Z, Jia K, Wang H, Gao F, Zhao S, Li F, et al. METTL14-regulated PI3K/Akt signaling pathway via PTEN affects HDAC5-mediated epithelial-mesenchymal transition of renal tubular cells in diabetic kidney disease. Cell Death Dis. 2021;12(1):1–32. https://doi.org/10.1038/s41419-020-03312-0.
[40] Yang K, Chen Z, Gao J, Shi W, Li L, Jiang S, et al. The key roles of GSK-3β in regulating mitochondrial activity. Cell Physiol Biochem. 2017;44(4):1445–59. https://doi.org/10.1159/000485580.
[41] You Q, Lin Y, Gong JH, Gui WY, Yan QH, Zou JD, et al. Integrating lipidomics, 16S rRNA sequencing, and network pharmacology to explore the mechanism of Qikui granule in treating diabetic kidney disease mice. J Chromatogr B Anal Technol Biomed Life Sci. 2025;1250:1–18. https://doi.org/10.1016/j.jchromb.2024.124378.
[42] Yu Y, Jia YY, Li HJ. Sodium butyrate improves mitochondrial function and kidney tissue injury in diabetic kidney disease via the AMPK/PGC-1α pathway. Ren Fail. 2023;45(2):1–15. https://doi.org/10.1080/0886022x.2023.2287129.
[43] Zhang C, Li Q, Lai S, Yang L, Shi G, Wang Q, et al. Attenuation of diabetic nephropathy by Sanziguben Granule inhibiting E. J Ethnopharmacol. 2017;205(1):207–16. https://doi.org/10.1016/j.jep.2017.05.009.
[44] Zhang L, Wang Z, Zhang X, Zhao L, Chu J, Li H, et al. Alterations of the gut microbiota in patients with diabetic nephropathy. Microbiol Spectr. 2022;10(4):322–4. https://doi.org/10.1128/spectrum.00324-22.
[45] Zhang Y, Jin D, Kang X, Zhou R, Sun Y, Lian F, et al. Signaling pathways involved in diabetic renal fibrosis. Front Cell Develop Biol. 2021;9(12):1–17. https://doi.org/10.3389/fcell.2021.696542.